We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Molecular diagnostics and personalized medicine major Myriad Genetics, Inc. (MYGN - Free Report) achieved another milestone as its EndoPredict test got positive coverage decision from Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies.
Notably, EndoPredict is Myriad Genetics’ next-generation, multigene prognostic test for breast cancer. The test provides information to help doctors devise personalized treatment plans.
Following the full implementation of these decisions, Myriad Genetics will have coverage for over 90% of breast cancer patients post implementation of these decisions.
Considering that EndoPredict has been used clinically in more than 15,000 patients, we areconfident about the growing adaptability of this test post the Medicare coverage approval.
As per a report provided by GBI Research, the global breast cancer treatment market will reach a worth of $17.2 billion by 2021, at a CAGR of 7.3%. Thus, the company clearly has bountiful prospects in this market.
Also, we note that the company has recently received extended Medicare coverage for its Prolasis test.
In this regard we note that, for the past three months, Myriad Genetics has been trading above the broader industry. The stock has gained 32.2%, higher than the industry’s gain of 4.5%.
Recent Developments
Myriad Genetics announced that its BRACAnalysis CDx companion diagnostic test successfully identified BRCA-mutated patients with HER2- metastatic breast cancer in the OlympiAD trial who responded better to treatment with olaparib than standard chemotherapy.
Also, Myriad Genetics presented favorable findings from its BRACAnalysis CDx test which successfully identified patients with metastatic breast cancer in Phase 3 OlympiAD Study.
Zacks Rank & Key Picks
Myriad Genetics carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are IDEXX Laboratories, Inc. (IDXX - Free Report) , Lantheus Holdings, Inc. (LNTH - Free Report) and Align Technology, Inc. (ALGN - Free Report) . Align Technology sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank #2 (Buy). You cansee the complete list of today’s Zacks #1 Rank stocks here.
Align Technology has a long-term expected earnings growth rate of 26.6%. The stock has rallied roughly 22.3% over the last three months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 70.4% over the last six months.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained around 6.8% over the last six months.
4 Surprising Tech Stocks to Keep an Eye on
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.
Image: Bigstock
Myriad Genetics' EndoPredict Gets Positive Coverage Decision
Molecular diagnostics and personalized medicine major Myriad Genetics, Inc. (MYGN - Free Report) achieved another milestone as its EndoPredict test got positive coverage decision from Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies.
Notably, EndoPredict is Myriad Genetics’ next-generation, multigene prognostic test for breast cancer. The test provides information to help doctors devise personalized treatment plans.
Following the full implementation of these decisions, Myriad Genetics will have coverage for over 90% of breast cancer patients post implementation of these decisions.
Considering that EndoPredict has been used clinically in more than 15,000 patients, we areconfident about the growing adaptability of this test post the Medicare coverage approval.
As per a report provided by GBI Research, the global breast cancer treatment market will reach a worth of $17.2 billion by 2021, at a CAGR of 7.3%. Thus, the company clearly has bountiful prospects in this market.
Also, we note that the company has recently received extended Medicare coverage for its Prolasis test.
In this regard we note that, for the past three months, Myriad Genetics has been trading above the broader industry. The stock has gained 32.2%, higher than the industry’s gain of 4.5%.
Recent Developments
Myriad Genetics announced that its BRACAnalysis CDx companion diagnostic test successfully identified BRCA-mutated patients with HER2- metastatic breast cancer in the OlympiAD trial who responded better to treatment with olaparib than standard chemotherapy.
Also, Myriad Genetics presented favorable findings from its BRACAnalysis CDx test which successfully identified patients with metastatic breast cancer in Phase 3 OlympiAD Study.
Zacks Rank & Key Picks
Myriad Genetics carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are IDEXX Laboratories, Inc. (IDXX - Free Report) , Lantheus Holdings, Inc. (LNTH - Free Report) and Align Technology, Inc. (ALGN - Free Report) . Align Technology sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank #2 (Buy). You cansee the complete list of today’s Zacks #1 Rank stocks here.
Align Technology has a long-term expected earnings growth rate of 26.6%. The stock has rallied roughly 22.3% over the last three months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 70.4% over the last six months.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained around 6.8% over the last six months.
4 Surprising Tech Stocks to Keep an Eye on
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.
See Stocks Now>>